A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Combination of searches for heavy spin-1 resonances using 139 fb−1 of proton-proton collision data at s = 13 TeV with the ATLAS detector

A combination of searches for new heavy spin-1 resonances decaying into different pairings of W, Z, or Higgs bosons, as well as directly into leptons or quarks, is presented. The data sample used corresponds to 139 fb−1 of proton-proton collisions at = 13 TeV collected during 2015–2018 with the ATLAS detector at the CERN Large Hadron Collider. Analyses selecting quark pairs (qq, bb, , and tb) or third-generation leptons (τν and ττ) are included in this kind of combination for the first time. A simplified model predicting a spin-1 heavy vector-boson triplet is used. Cross-section limits are set at the 95% confidence level and are compared with predictions for the benchmark model. These limits are also expressed in terms of constraints on couplings of the heavy vector-boson triplet to quarks, leptons, and the Higgs boson. The complementarity of the various analyses increases the sensitivity to new physics, and the resulting constraints are stronger than those from any individual analysis considered. The data exclude a heavy vector-boson triplet with mass below 5.8 TeV in a weakly coupled scenario, below 4.4 TeV in a strongly coupled scenario, and up to 1.5 TeV in the case of production via vector-boson fusion

Combined measurement of the Higgs boson mass from the H → γγ and H → ZZ∗ → 4ℓ decay channels with the ATLAS detector using √s = 7, 8, and 13 TeV pp collision data

A measurement of the mass of the Higgs boson combining the H → Z Z ∗ → 4 ℓ and H → γ γ decay channels is presented. The result is based on 140     fb − 1 of proton-proton collision data collected by the ATLAS detector during LHC run 2 at a center-of-mass energy of 13 TeV combined with the run 1 ATLAS mass measurement, performed at center-of-mass energies of 7 and 8 TeV, yielding a Higgs boson mass of 125.11 ± 0.09 ( stat ) ± 0.06 ( syst ) = 125.11 ± 0.11     GeV . This corresponds to a 0.09% precision achieved on this fundamental parameter of the Standard Model of particle physics

Antiproliferative and proapoptotic activities of hydroxytyrosol derivatives on human promyelocytic leukemia cell lines

Purpose Hydroxytyrosol (3,4-DHPEA) derivatives (disulfide, thioacetate and thiohydroxytyrosol) were synthesized in order to test in vitro if the combination of catechol moiety of 3,4-DHPEA and sulfur containing functions results in an improvement of the pro-apoptotic and anti-proliferative activities shown by 3,4-DHPEA. The involvement of H2O2 production in the cell culture medium has been studied. Methods The effects of thiohydroxytyrosol derivatives and 3,4-DHPEA on cell proliferation, apotosis and cell cycle of HL60 and its MDR variant HL60R were assessed by the Trypan Blue exclusion test, by fluorescence microscopy or by flow cytometry respectively. H2O2 concentrations in the culture medium was measured by the ferrous ion oxidation-xylenol orange method. Results We found that: i) all synthesized compounds were able to inhibit the proliferation inducing apoptosis on both cell lines HL60 and HL60R; ii) all thiohydroxytyrosol derivatives were more effective than 3,4-DHPEA in inducing apoptosis on HL60R; iii) differently from 3,4-DHPEA, the proapoptotic activities of thiohydroxytyrosol derivatives were not dependent upon the release of H2O2 in the culture medium; iv) the hydroxytyrosol disulfide was the most active pro-apoptotic and anti-proliferative compound on both HL60 and HL60R cells. Conclusions The combination of cathecol moiety and sulfur functions resulted in an improvement of 3,4-DHPEA proapoptotic activity which was particularly evident on HL60R cells suggesting that these compounds could be potentially used in cancer therapy and could be able to reverse the resistance toward the most common anticancer drugs